- Galena Biopharma (GALE -6.4%) opens with a thud after Jim Cramer suggests investors take profits after shares more than tripled during the past three months.
- Cramer questioned CEO Dr. Mark Ahn about the history of failures for drugs similar to NeuVax, GALE's lead clinical candidate, saying he was skeptical about the drug's chances for approval.
- In response to criticisms, Ahn says "of the patients in the Phase II study of NeuVax, 0% of those patients had a recurrence of cancer."
Galena Biopharma -6.4% as Jim Cramer says take profits
Jan 17 2014, 09:45 ET